Skip to main content
SpringerLink
Log in

Special situations, market fragmentation II: sex differences

  • Chapter
Clinical Pharmacology: Current Topics and Case Studies

  • 2724 Accesses

3

Delivering the right drug at the right dose to the right patient is one of the basic tenets of clinical pharmacology and personalized medicine. Recognition of the disparities in men’s and women’s health, including shortcomings in traditional medical practice and unmet scientific needs, has provided the necessary springboard for substantial therapeutic advances and will continue to pave the way for further advances in the field. Detecting sex differences in drug trials is a step toward an era of personalized medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Statistik Austria (www.statistik.at)

  2. Uhl K (2008) Advancing Women’s health in the 21st century: applying the tools of clinical pharmacology. Clin Pharmacol Ther 83: 3–7

    Article  PubMed  CAS  Google Scholar 

  3. Anonymous (2001) Exploring the biological contributions to human health: does sex matter? J Womens Health Gend Based Med 10: 433–439

    Article  Google Scholar 

  4. Sapienza C. Institute of Medicine Report — “Exploring the biological contributions to human health: Does sex matter?” Gender analysis of medications: challenges to the sciences and profession of pharmacy. Presented at the 62nd FIP Congress, September 1–5, 2002; Nice, France. Abstract #AS-S-002.

    Google Scholar 

  5. Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics. Clin Pharmacokinet 41: 329–342

    Article  PubMed  CAS  Google Scholar 

  6. Gross JL, Friedman R, Azevedo MJ, Silveiro SP, Pecis M (1992) Effect of age and sex on glomerular filtration rate measured by 51Cr-EDTA. Braz J Med Biol Res 25: 129–134

    PubMed  CAS  Google Scholar 

  7. Bennett JC and the Board on Health Sciences Policy of the Institute of Medicine (1993) Inclusion of women in clinical trials — policies for population subgroups. N Engl J Med 329: 288–292

    Article  PubMed  CAS  Google Scholar 

  8. Institute of Medicine, Committee on the Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies (1994) Women and Health Research: ethical and Legal Issues of Including Women in Clinical Studies, Vol. 1. National Academy Press, Washington, DC

    Google Scholar 

  9. Haack S, Seeringer A, Thürmann PA, Becker T, Kirchheiner J (2009) Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics 10(9): 1511–1526

    Article  PubMed  CAS  Google Scholar 

  10. Aerssens J, Paulussen AD (2005) Pharmacogenomics and acquired long QT syndrome. Pharmacogenomics 6(3): 259–270

    Article  PubMed  CAS  Google Scholar 

  11. Meinert CL, Gilpin AK, Unalp A, Dawson C (2000) Gender representation in trials. Control Clin Trials 21: 462–475

    Article  PubMed  CAS  Google Scholar 

  12. Vidaver RM, Lafleu B, Tong C, Bradshaw R, Marts SA (2000) Women subjects in NIH-funded clinical research literature: lack of progress in both representation and analysis by sex. J Womens Health Gend Based Med 9: 495–504

    Article  PubMed  CAS  Google Scholar 

  13. Harris DJ, Douglas PS (2000) Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 343: 475–480

    Article  PubMed  CAS  Google Scholar 

  14. Müllner M, Vamvakas S, Rietschel M, van Zwieten-Boot BJ (2007) Are women appropriately represented and assessed in clinical trials submitted for marketing authorization? A review of the database of the European Medicines Agency. Int J Clin Pharmacol Ther 45(9): 477–484

    PubMed  Google Scholar 

  15. Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42: 107–121

    Article  PubMed  CAS  Google Scholar 

  16. Anderson GD (2008) Gender differences in pharmacological response. Int Rev Neurobiol 83: 1–10

    Article  PubMed  Google Scholar 

  17. Cotreau MM, von Moltke LL, Greenblatt DJ (2005) The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44: 33–60

    Article  PubMed  CAS  Google Scholar 

  18. Wolbold R, Klein K, Burk O, et al. (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38: 978–988

    PubMed  CAS  Google Scholar 

  19. Hreiche R, Morissette P, Turgeon J (2008) Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend Med 5(2): 124–135

    Article  PubMed  Google Scholar 

  20. Ebert SN, Liu XK, Woosley RL (1998) Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health 7(5): 547–557

    Article  PubMed  CAS  Google Scholar 

  21. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1; 270(21): 2590–2597

    Article  PubMed  CAS  Google Scholar 

  22. Hogstedt S, Lindberg B, Rane A (1983) Increased oral clearance of metoprolol in pregnancy. Eur J Clin Pharmacol 24: 217–220

    Article  PubMed  CAS  Google Scholar 

  23. Llerena A, Cobaleda J, Martinez C, Benitz J (1996) Interethnic differences in drug metabolism: influence of genetic and environmental factors on desrisoquine hydroxylation phenotype. Eur J Drug Metabol Pharmacokinet 21: 129–138

    Article  CAS  Google Scholar 

  24. Wadelius M, Darj E, Frenne G, Rane A (1997) Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 62: 400–407

    Article  PubMed  CAS  Google Scholar 

  25. Rademaker M (2001) Do women have more adverse drug reactions? Am J Clin Dermatol 2(6): 349–351

    Article  PubMed  CAS  Google Scholar 

  26. Keitt SK, Wagner CR, Tong C, Marts SA (2003) Understanding the biology of sex and gender differences: using subgroup analysis and statistical design to detect sex differences in clinical trials. MedGenMed 5(2): 39

    PubMed  Google Scholar 

  27. Pregnancy discrimination act of 1978, 92 Stat. 2076; 42 USC 2000e(k). 39

    Google Scholar 

  28. Recruitment and Retention of Women in Clinical Studies (1995) Office of Research on Women’s Health. Bethesda, MD, NIH Pub No. 95-3756

    Google Scholar 

  29. Killien M, Bigby JA, Champion V, et al. (2000) Involving minority and underrepresented women in clinical trials: The National Centers of Excellence in Women’s Health. J Womens Health Gend Based Med 9: 1061–1070

    Article  PubMed  CAS  Google Scholar 

  30. Underwood SM (2000) Minorities, women and clinical cancer research: the charge, promise, and challenge. Ann Epidemiol 10: S3–S12

    Article  PubMed  CAS  Google Scholar 

  31. Brown DR, Fouad MN, Basen-Engquist KB, Tortolero-Luna G (2000) Recruitment and retention of minority women in cancer screening, prevention, and treatment trials. Ann Epidemiol 10: S13–S21

    Article  PubMed  CAS  Google Scholar 

  32. Wilcox S, Shumaker SA, Bowen DJ, et al. (2001) Promoting adherence and retention to clinical trials in special populations: a women’s health initiative workshop. Control Clin Trials 22: 279–289

    Article  PubMed  CAS  Google Scholar 

  33. Fisher B, Costantino JP, Wickerham DL, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388

    Article  PubMed  CAS  Google Scholar 

  34. Food and Drug Administration (1993) Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs, notice. Fed Reg 58: 39405–39416.

    Google Scholar 

  35. Anger GJ, Piquette-Miller M (2008) Pharmacokinetic studies in pregnant women. Clin Pharmacol Ther 83(1): 184–187

    Article  PubMed  CAS  Google Scholar 

  36. Dawes M, Chowienczyk PJ (2001) Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 15(6): 819–826

    Article  PubMed  CAS  Google Scholar 

  37. Connor sperling gelber (1994) Reduction of maternal-infant transmission of HIV with zidovudine treatment. N Engl J Med 331: 1173–1180

    Article  PubMed  CAS  Google Scholar 

  38. World Health Organization Statistical Information System 2004. www.who.int/whosis/

  39. Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A (2009) Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987–2003 from the Swedish Hospital Discharge Registry. Eur Heart J 30(6): 671–678

    Article  PubMed  Google Scholar 

  40. Vaccarino V, Krumholz HM, Berkman LF, Horwitz RI (1995) Sex differences in mortality after myocardial infarction: is there evidence for an increased risk for women? Circulation 91: 1861–1871

    PubMed  CAS  Google Scholar 

  41. Milcent C, Dormont B, Durand-Zaleski I, Steg PG (2007) Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 Nationwide French Hospitals Database. Circulation 115: 833–839

    Article  PubMed  Google Scholar 

  42. Anderson RD, Pepine CJ (2007) Gender differences in the treatment for acute myocardial infarction: bias or biology? Circulation 20; 115(7): 823–826

    Article  Google Scholar 

  43. Chandra NC, Ziegelstein RC, Rogers WJ, et al. (1998) Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. Arch intern Med 158: 981–988

    Article  PubMed  CAS  Google Scholar 

  44. Bairey Merz CN, Johnson BD, et al. (2003) Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 41: 413–419

    Google Scholar 

  45. Herity NA, Lo S, Lee DP, et al. (2003) Effect of a change in gender on coronary arterial size: a longitudinal intravascular ultrasound study in transplanted hearts. J Am Coll Cardiol 41: 1539–1546.

    Article  PubMed  Google Scholar 

  46. Holubkov R, Karas RH, Pepine CJ, et al. (2002) Large brachial artery diameter is associated with angiographic coronary artery disease in women. Am Heart J 143: 802–807

    Article  PubMed  Google Scholar 

  47. Sharaf BL, Shaw L, Johnson BD, et al. (2004) Any measurable coronary artery disease identified in women presenting with ischemic chest pain is associated with an adverse outcome: findings from the NIH-NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study angiographie core laboratory. J Am Coll Cardiol 43: 292A

    Article  Google Scholar 

  48. Rauscher FM, Goldschmidt-Clermont PJ, et al. (2003) Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 108: 457–463

    Article  PubMed  Google Scholar 

  49. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V (2005) Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 26: 1585–1595

    Article  PubMed  CAS  Google Scholar 

  50. Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273: 1450–1456

    CAS  Google Scholar 

  51. Shekelle PG, Rich MW, Morton SC, et al. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. J Am Coll Cardiol 41: 1529–1538

    Article  PubMed  CAS  Google Scholar 

  52. Fiather MD, Yusuf S, Kober L, et al. (2000) The ACE inhibitor myocardial infarction collaborative group. Long-term ACE inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355: 1575–1581

    Google Scholar 

  53. Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR, Schwartz JB (2000) Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 68: 130–142

    Article  PubMed  CAS  Google Scholar 

  54. Blaustein MP, Robinson SW, Gottlieb SS, Balke CW, Hamlyn JM (2003) Sex, digitalis, and the sodium pump. Mol Interv 3: 68–72

    Article  PubMed  CAS  Google Scholar 

  55. Furberg CD, Vittinghoff E, Davidson M, et al. (2002) Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation 105: 917–922

    Article  PubMed  Google Scholar 

  56. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL (2001) Drug-induced QT prolongation in women during the menstrual cycle. JAMA 285: 1322–1326

    Article  PubMed  CAS  Google Scholar 

  57. Bednar MM, Harrigan EP, Ruskin JN (2002) Torsades de pointes associated with nonantiar-rhythmic drugs and observations on gender and QTc. Am J Cardiol 89: 1316–1319

    Article  PubMed  CAS  Google Scholar 

  58. Ho PC, Triggs EJ, Bourne DW, Heazlewood VJ (1985) The effect of age and sex on the disposition of acetylsalicyl acid and its metabolites. Br J Clin Pharmacol 19: 675–684

    PubMed  CAS  Google Scholar 

  59. De Berardis G, Sacco M, Pellegrini F, Graziano G, Tognoni G, Nicolucci A (2009) Aspirin for primary prevention of cardiovascullar events in people with diabetes: meta-analysis of randomised controller trials. BMJ 339: b4531.

    Article  PubMed  Google Scholar 

  60. FDA. CDER. Report no.: http:www.fda.gov/cder/foi/label2001/207S6lbl.pdf.

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Vienna General Hospital (AKH), Medical University Vienna, Vienna, Austria

    Ghazaleh Gouya

Authors
  1. Ghazaleh Gouya
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Clinical Pharmacology, Medical University Vienna, Vienna General Hospital (AKH), Vienna, Austria

    Markus Müller (Professor and Head of Department) (Professor and Head of Department)

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag/Wien

About this chapter

Cite this chapter

Gouya, G. (2010). Special situations, market fragmentation II: sex differences. In: Müller, M. (eds) Clinical Pharmacology: Current Topics and Case Studies. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0144-5_25

Download citation

Publish with us

Policies and ethics

Search

Navigation